The FDA has updated Actos label warnings with additional study information and reinforced its belief that the diabetes drug's side effects may increase the risk of bladder cancer.
Onglyza and similar diabetes drugs may increase the risk of heart failure, according to an FDA warning that will lead to new label warnings being added to the drugs.
As sales of the brand-name version of the diabetes drug Actos continue fall amid mounting injury lawsuits and recent generic competition, Takeda Pharmaceuticals has launched a trio of new drugs…
